|
 
- 现金
- 609 元
- 精华
- 0
- 帖子
- 367
- 注册时间
- 2011-9-27
- 最后登录
- 2022-11-15
|
To: lovecloudy
From:
Hepatitis B Virus Resistance to Nucleos(t)ide Analogues
REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY
GASTROENTEROLOGY 2009;137:1593–1608
Authors: FABIEN ZOULIM*,‡,§ and STEPHEN LOCARNINI
*INSERM, U871, Lyon; ‡Université Lyon 1, Lyon; §Hospices Civils de Lyon, Service d’hépatologie et de gastroentérologie, Lyon, France; and Victorian Infectious
Diseases Reference Laboratory, North Melbourne, Victoria, Australia
Lamivudine resistance: 23% (1year) to 80%(5 year)
entecavir(naive) resistance: 0.2%(1 year) to 1.2% (6 year)
Entecavir (LAM resistant): 6%(1 year), 15%(2 years) to 51%(5 years)
tenofovir resistance: 0% (1year) to 0% (2 year)
Because drug-resistant mutant HBV populations are
established and expand through replication, antiviral
therapy, once initiated, should aim to suppress viral replication
as completely and rapidly as possible. The lower
risk of resistance to TDF and ETV (compared with LMV,
LdT, and ADV) supports their use as first-line therapy,
Since tenofovir is not available in China at this time, entecavir should be used as first line antiviral medicine.
This is the reason I am so against Dr. 王震宇 who is still advocating LAM as first choice to treat HBVer.
Dan |
|
发表于 2011-10-28 20:08
